BMS207147 is a orally-available, triazole-based antifungal with MICs 2- to 4-fold more potent than itraconazole and 40-fold more active than fluconazole against yeasts. In all but 9 of 116 Candida strains tested, BMS207147 had MICs of < 0.5 ug/mL. [1] In oral mouse studies, BMS207147 was shown to have a 3-fold longer half-life than itraconazole. [2]
In 541 clinical isolates of Cryptococcus neoformans, BMS207147 again proved to be more potent than itraconazole and fluconazole (0.25 ug/mL vs 0.5 ug/mL and 8 ug/mL). [3]
Technical information:
| Chemical Formula: | C22H17F2N5OS | |
| CAS #: | 182760-06-1 | |
| Molecular Weight: | 437.47 | |
| Purity: | > 98% | |
| Appearance: | White | |
| Chemical Name: | 4-[2-[(2R,3R)-3-(2,4-difluorophenyl)-3-hydroxy-4-(1,2,4-triazol-1-yl)butan-2-yl]-1,3-thiazol-4-yl]benzonitrile | |
| Solubility: | Up to 22 mM in DMSO | |
| Synonyms: | BMS-207147, BMS 207147, BMS207147, Ravuconazole, ER-30346 |
Shipping Condition: The product is shipped in a glass vial at ambient temperature.
Storage condition: For longer shelf life, store solid powder at 4oC desiccated, or store DMSO solution at -20oC.
Reference:
| 1. | Fung-Tomc et al., In vitro activity of a new oral triazole, BMS-207147 (ER-30346). Antimicrob. Agents Chemother. 1998, 42(2), 313-318. Pubmed ID: 9527778 |
| 2. | Yamazumi et al., In vitro activities of BMS-207147 against over 600 contemporary clinical bloodstream isolates of Candida species from the SENTRY Antimicrobial Surveillance Program in North America and Latin America. Antimicrob. Agents Chemother. 1999, 43(9), 2236-2239. Pubmed ID: 10471571 |
| 3. | Yamazumi et al., In vitro activities of ravuconazole (BMS-207147) against 541 clinical isolates of Cryptococcus neoformans. Antimicrob. Agents Chemother. 2000, 44(10), 2883-2886. Pubmed ID: 10991880 |
Other Information:
Product Specification (pdf)
MSDS (pdf)
Certificate of Analysis is available upon request.
